D
David W. Hogg
Researcher at University of Toronto
Publications - 121
Citations - 29207
David W. Hogg is an academic researcher from University of Toronto. The author has contributed to research in topics: Melanoma & Germline mutation. The author has an hindex of 34, co-authored 113 publications receiving 25771 citations. Previous affiliations of David W. Hogg include University Health Network & Princess Margaret Cancer Centre.
Papers
More filters
Journal ArticleDOI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
TL;DR: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Journal ArticleDOI
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman,Axel Hauschild,Caroline Robert,John B. A. G. Haanen,Paolo A. Ascierto,James Larkin,Reinhard Dummer,Claus Garbe,Alessandro Testori,Michele Maio,David W. Hogg,Paul Lorigan,Céleste Lebbé,Thomas Jouary,Dirk Schadendorf,Antoni Ribas,Jeffrey A. Sosman,John M. Kirkwood,Brigitte Dréno,K. B. Nolop,Jiang Li,B. Nelson,Jeannie Hou,Richard J. Lee,Keith T. Flaherty,Grant A. McArthur +25 more
TL;DR: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation in a phase 3 randomized clinical trial.
Journal ArticleDOI
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine
James Larkin,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,Piotr Rutkowski,Christopher D. Lao,Charles Lance Cowey,Dirk Schadendorf,John Wagstaff,R. Dummer,Pier Francesco Ferrucci,Michael Smylie,David W. Hogg,A. Hill,Ivan Marquez-Rodas,John B A G Haanen,Massimo Guidoboni,Michele Maio,Patrick Schöffski,M.S. Carlino,C. Lebbé,Grant A. McArthur,Paolo A. Ascierto,G.A. Daniels,Georgina V. Long,Lars Bastholt,Jasmine I. Rizzo,A. Balogh,Andriy Moshyk,F.S. Hodi,Jedd D. Wolchok +30 more
TL;DR: Among patients with advanced melanoma, sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab or nivoliumab alone than in those who received ipil optimumab alone, with no apparent loss of quality of life in the patients whoreceived regimens containing nivolinumab.
Journal ArticleDOI
Binary companions of evolved stars in APOGEE DR14: Search method and catalog of ~5,000 companions
Adrian M. Price-Whelan,David W. Hogg,Hans-Walter Rix,Nathan De Lee,Steven R. Majewski,David L. Nidever,Nicholas Troup,José G. Fernández-Trincado,D. A. García-Hernández,Penélope Longa-Peña,Christian Nitschelm,Jennifer Sobeck,Olga Zamora +12 more
TL;DR: In this paper, a Monte Carlo sampler (The Joker) is used to perform a search for companions to 96,231 red-giant stars observed in the APOGEE survey (DR14) with $3$ spectroscopic epochs.
Journal ArticleDOI
The Broad-band Optical Properties of Galaxies with Redshifts 0.0 < z < 0.2
M. R. Blanton,David W. Hogg,N. A. Bahcall,Ivan K. Baldry,J. Brinkmann,I. Csabai,Daniel J. Eisenstein,Masataka Fukugita,James E. Gunn,Z. Ivezic,D. Q. Lamb,Robert H. Lupton,Jonathan Loveday,Jeffrey A. Munn,Robert C. Nichol,S. Okamura,David J. Schlegel,K. Shimasaku,Michael A. Strauss,Michael S. Vogeley,David H. Weinberg +20 more
TL;DR: In this paper, the Sersic index was used to measure the radial profile shape of the galaxies in the Sloan Digital Sky Survey (SDSS), and the dependence of local galaxy density (smoothed on 8 h^{-1} Mpc scales) on all of these properties.